Effectiveness Of Lanadelumab For Preventing Hereditary Angioedema Attacks: Subgroup Analyses From The Help Study

Hereditary angioedema (HAE) is a rare disease that affects 1:50,000 people and is characterized by unpredictable attacks of angioedema affecting the skin and submucosal tissue. Patients with HAE must have medication readily available to treat attacks, and may use long-term prophylaxis (LTP) to prevent attacks. Approved therapeutics for LTP include the plasma kallikrein inhibitors lanadelumab and berotralstat; C1-inhibitor (C1-INH) replacement; and androgens.